New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs ...

Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout six-month follow-up period ...

NIEL, Belgium and BOSTON, MA, USA I January 9, 2025 I etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based ...

OTTAWA, Canada I January 9, 2025 I Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing ...

The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...

SHANGHAI, China I January 9, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone ...

Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ ...

In both clinical trials, lixudebart demonstrated a favorable safety profile, both as a monotherapy and in combination with standard of care (n=51 active patients across the two trials). These findings ...

BEIJING, China & PRAGUE, Czech Republic I January 09, 2025 I Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing ...

BEIJING, China I January 8, 2025 I In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide ...

CHICAGO, IL, USA I January 8, 2025 I Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical ...

LONDON, UK & SAN FRANCISCO, CA, USA I January 09, 2025 I Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage ...